Grant program for qualified and approved cfDNA Researchers in academia and non-profit organizations for the purpose of advancing their research projects by providing more cfDNA and ctDNA than is available using current methods.
IRVINE, Calif., Jun 8, 2021– nRichDX® Inc. announces the Revolution™ Sample Prep Grant Program which provides grants of Processor hardware and Revolution kits to researchers extracting circulating free DNA and circulating tumor DNA in their work. The Revolution Sample Prep System enables the extraction of more cfDNA and ctDNA from samples of blood or urine. The System extracts from 1 mL - 20 mL in a single extraction and unlike other methods, does not require cfDNA yield-lowering sample pooling, concentration, or transfer steps.
Grants are limited and are limited to Researchers in academia and non-profit organizations. Prospective grant applicants may apply by completing a short qualification form at: https://www.nrichdx.com/nrichdx-research-grant-landing-page
The Revolution Semi-Automated Workflow’s current application is for the extraction of cfDNA and ctDNA from plasma and urine for liquid-based assay development, with other applications in the near-term development pipeline for CTCs, exosomes, infectious disease wastewater monitoring, RNA, and total cell-free nucleic acid.
nRichDX® Inc, based in California, is an emerging leader in liquid-based assay sample prep solutions that enable customers to extract much more analysis-ready target as compared to existing methods. The company’s patented Revolution™ Sample Prep System is the first and only high-yield, IVD-labeled liquid biopsy sample prep platform that can process a wide range of total volumes from 1 mL - 50 mL in a single magnetic bead-based extraction, without the yield-lowering pooling, transfer, or concentration steps other methods require. nRichDX solves one of precision medicine’s greatest problems – – inaccurate or failed assays due to a lack of target material. The Revolution System greatly enhances test sensitivity and enables testing for earlier detection, monitoring, timely treatment, and optimal patient outcomes. More information at www.nrichdx.com